Biogen (BSP:BIIB34) Cyclically Adjusted Book per Share: R$74.39 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:BIIB34 Biogen Inc BSP:BIIB34
62 GF Score
Price R$188.29
GF Value R$166.19
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Book per Share?

Biogen BSP:BIIB34 62 Cyclically Adjusted Book per Share is R$74.39 as of Jun. 2026. GuruFocus rates BSP:BIIB34 with a GF Score™ of 62/100 and a GF Value™ of R$166.19 (Modestly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Biogen's adjusted book value per share for the three months ended in Jun. 2026 was R$108.545. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$74.39 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Book Growth Rate was 10.40% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 10.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 12.00% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Biogen was 60.90% per year. The lowest was 8.90% per year. And the median was 13.60% per year.

As of today (2026-08-28), Biogen's current stock price is R$188.29. Biogen's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was R$74.39. Biogen's Cyclically Adjusted PB Ratio of today is 2.53.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.77.


Biogen  (BSP:BIIB34) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=188.29/74.39
=2.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Biogen was 9.94. The lowest was 1.31. And the median was 4.77.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Biogen Cyclically Adjusted Book per Share Related Terms


Biogen Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Book per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.35 60.62 61.72 86.08 85.43

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 88.93 79.95 85.43 85.74 74.39

BSP:BIIB34 vs OGN, AMRN, SCLX: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PB Ratio falls into.


BSP:BIIB34
62GF Score
Biogen Inc BSP:BIIB34
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=108.545/333.9520*333.9520
=108.545

Current CPI (Jun. 2026) = 333.9520.

Biogen Quarterly Data

Book Value per Share CPI Adj_Book
201609 30.076 241.428 41.602
201612 31.292 241.432 43.284
201703 27.848 243.801 38.145
201706 29.974 244.955 40.864
201709 31.622 246.819 42.785
201712 32.619 246.524 44.187
201803 36.253 249.554 48.514
201806 38.101 251.989 50.494
201809 46.602 252.439 61.650
201812 42.626 251.233 56.661
201903 45.171 254.202 59.342
201906 44.862 256.143 58.490
201909 52.616 256.759 68.435
201912 52.189 256.974 67.823
202003 60.830 258.115 78.703
202006 61.528 257.797 79.704
202009 62.664 260.280 80.401
202012 59.962 260.474 76.877
202103 66.351 264.877 83.654
202106 60.194 271.696 73.987
202109 62.218 274.310 75.746
202112 69.581 278.802 83.345
202203 62.963 287.504 73.135
202206 68.514 296.311 77.217
202209 77.224 296.808 86.888
202212 81.014 296.797 91.156
202303 82.382 301.836 91.148
202306 80.499 305.109 88.109
202309 81.947 307.789 88.913
202312 83.073 306.746 90.441
202403 86.849 312.332 92.861
202406 98.178 314.175 104.358
202409 103.214 315.301 109.319
202412 116.178 315.605 122.932
202503 110.778 319.799 115.681
202506 110.736 322.561 114.647
202509 110.493 324.800 113.606
202512 112.631 324.054 116.071
202603 109.700 330.213 110.942
202606 108.545 333.952 108.545

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of R$74.39 mean?
Biogen (BSP:BIIB34) has a Cyclically Adjusted Book per Share of R$74.39 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Book per Share too high?
Biogen's current Cyclically Adjusted Book per Share is R$74.39. Overall, Biogen has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Book per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Book per Share of R$74.39 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Book per Share is R$74.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (BSP:BIIB34) is currently considered Modestly Overvalued. The stock's GF Value™ is R$166.19, compared to a current price of R$188.29 — trading 13.3% above its estimated fair value. The current Cyclically Adjusted Book per Share is R$74.39. Biogen's overall GF Score™ is 62/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Biogen (BSP:BIIB34), the current Cyclically Adjusted Book per Share is R$74.39 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (BSP:BIIB34) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of R$188.29 is trading 13.3% above its estimated GF Value™ of R$166.19. GuruFocus considers Biogen to be Modestly Overvalued.

Key valuation signals for BSP:BIIB34:

  • Cyclically Adjusted Book per Share: R$74.39
  • GF Value™: R$166.19 vs. price of R$188.29 (13.3% above fair value)
  • GF Score™: 62/100 with 10 warning signs

No single metric tells the full story. See the BSP:BIIB34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
62GF Score

Get the complete analysis for BSP:BIIB34

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$188.29
Price
R$166.19
GF Value